Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

Inclusion Criteria: * Histologically or cytologically proven carcinoma of the pancreas that is locally advanced * ECOG performance status 0- 2 * Adequate labs * No prior abdominal radiation therapy * No other concurrent clinically evident malignancy, except inactive nonmelanoma skin cancer, inactive cervical cancer, or other cancer for which the patient has been disease-free for 5 years * All disease must be encompassed within a radiotherapy portal * Not pregnant or nursing Exclusion Criteria: * Patient has metastatic disease on radiological staging * systemic therapy. * Patient has known active infection with HIV, hepatitis C or hepatitis B * Patient has serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the patient to receive an experimental research drug. * Patient is deemed to be have obvious resectable disease at presentation * Received any investigational agent within a month prior to enrollment. * Neuroendocrine tumors of the pancreas